Evidence map›Paper›PMID 40343501›Full record

ArticleCellular and molecular life sciences : CMLS2025

Human-specific genomic evolution of a regulatory network enables fine-tuning of N-cadherin gene expression.

Éva Erdmann, Savera Agolli, Simon Fix, Félicie Cottard, Christine Keyser, Vincent Zvenigorosky, Angéla Gonzalez, Zakary Haili, Bruno Kieffer, Jocelyn Céraline

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Éva ErdmannCNRS UMR 7104, INSERM U1258, IGBMC, Université de Strasbourg, Illkirch, 67404, France.
Savera AgolliCNRS UMR 7104, INSERM U1258, IGBMC, Université de Strasbourg, Illkirch, 67404, France.
Simon FixCNRS UMR 7104, INSERM U1258, IGBMC, Université de Strasbourg, Illkirch, 67404, France.
Félicie CottardCNRS UMR 7242, ESBS, Université de Strasbourg, Illkirch, 67404, France.
Christine KeyserCNRS UMR 8045 BABEL, Université de Paris, Paris, 75012, France.
Vincent ZvenigoroskyCNRS UMR 8045 BABEL, Université de Paris, Paris, 75012, France.
Angéla GonzalezStrasbourg Institute of Legal Medicine, Strasbourg, 67085, France.
Zakary HailiCNRS UMR 7104, INSERM U1258, IGBMC, Université de Strasbourg, Illkirch, 67404, France.
Bruno KiefferCNRS UMR 7104, INSERM U1258, IGBMC, Université de Strasbourg, Illkirch, 67404, France.
Jocelyn CéralineCNRS UMR 7104, INSERM U1258, IGBMC, Université de Strasbourg, Illkirch, 67404, France. ceraline@unistra.fr.ORCID http://orcid.org/0000-0001-6476-8797

Funding

Agence Nationale de la Recherche ANR-20-CE11-0004 ARCHAPAssociation Alsace contre le Cancer Association Alsace contre le CancerAssociation pour la Recherche sur les Tumeurs de la Prostate Association pour la Recherche sur les Tumeurs de la Prostate
6 · The paper itself

Abstract

Androgen receptor (AR), a member of the nuclear receptor superfamily controls prostate epithelial cell plasticity by repressing a panel of genes involved in epithelial-mesenchymal transition (EMT), including the human CDH2 gene encoding N-cadherin. At the opposite, pathological AR variants such as AR-V7 associated with prostate tumor progression upregulate those EMT genes. Here, focusing on the human CDH2 gene, we show that this duality between AR and AR-V7 relies on a potential human accelerated region present in the intron 1. This fastest-evolving region of the human genome is actually a variable number tandem repeat (VNTR) comprising 24 repetitions of a DNA sequence that englobes binding sites for steroid hormone receptors, recombination signal binding protein for immunoglobulin kappa j region (RBPJ) an effector of the Notch pathway, and zinc finger e-box binding homeobox 1 (ZEB1). Genomic DNA sequencing, multiple sequence alignment, data mining, as well as protein-DNA interaction and gene expression analyses indicate that this VNTR constitutes a potential transcriptional hub for different transcription factors to control human CDH2 expression. Also, our data suggest that prostate tumor cells may unlock an up to now unknown molecular mechanism associated with a fine-tuned control of human CDH2 gene expression.

Indexed as

Antigens, CDCadherinsEvolution, MolecularGene Regulatory NetworksGenome, HumanEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansImmunoglobulin J Recombination Signal Sequence-Binding ProteinMaleMinisatellite RepeatsProstatic NeoplasmsReceptors, AndrogenZinc Finger E-box-Binding Homeobox 1Antigens, CDAR protein, humanCadherinsCDH2 protein, humanImmunoglobulin J Recombination Signal Sequence-Binding ProteinRBPJ protein, humanReceptors, AndrogenZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1Androgen receptorAR-V7CDH2Cell plasticityN-cadherinProstate cancerTranscriptional regulation

Identifiers

PMID40343501
PMCPMC12064536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.